Development and Validation of Blood-Based Predictive Biomarkers for Response to PD-1/PD-L1 Checkpoint Inhibitors: Evidence of a Universal Systemic Core of 3D Immunogenetic Profiling across Multiple Oncological Indications

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) offer high efficacy of cancer treatment, but their use is limited to a subset of patients who respond well to the resetting of the immune system. To attempt to identify patients and predict response to ICI, tumour-based biomarkers such as PD-L1 exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunter, Ewan, Salter, Matthew, Powell, Ryan, Dring, Ann, Naithani, Tarun, Chatziioannou, Maria Eleni, Gebregzabhar, Abel, Issa, Mutaz, Green, Jayne, Ng, Serene, Lim, Chun Ren, Keat, Cheah Soon, Suan, Ang Tick, Raman, Rakesh, Fatt, Ho Kean, Luen, Fabian Lee Wei, Alshaker, Heba, Pchejetski, Dmitri, Blum, Dave, Guiel, Thomas, Heaton, Robert, Levine, Jedd, Akoulitchev, Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216232/
https://www.ncbi.nlm.nih.gov/pubmed/37345033
http://dx.doi.org/10.3390/cancers15102696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216232/
https://www.ncbi.nlm.nih.gov/pubmed/37345033
http://dx.doi.org/10.3390/cancers15102696

Ejemplares similares